Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROWD-COMPARE
2022-503010-23-01Phase 4Authorised
- Sponsor
- University Hospital Odense
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of carvedilol and metoprolol in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by University Hospital Odense. Primary endpoint: Primary combined endpoint. Planned start Jun 2023; status: authorised.
02
Drugs
carvedilolmetoprolol
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2022-503010-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503010-23-01.